How Peter Marks' FDA departure is impacting pharma, biotech stocks
The abrupt resignation announcement that came late on Friday, March 28, from Peter Marks, who heads the U.S. FDA's Center for Biologics Evaluation and Research, has sent reverberations throughout the ...